Companion Diagnostics

News on companion diagnostics and drug/test co-development.

Merck KGaA Advancing Tepotinib in MET-Altered Cancer Subpopulations

Premium

The German drugmaker plans to advance the NSCLC treatment in parallel with tissue-based and liquid biopsy companion assays that can identify best responders.

Myriad Genetics Submits Supplementary PMA for BRACAnalysis CDx

The FDA will consider the companion diagnostic application alongside data for Pfizer's talazoparib in BRCA-mutated advanced breast cancer.

Janssen Plans Year-End Erdafitinib Filing Based on Phase II Data in FGFR-Mutated Bladder Cancer

Premium

The company is planning to submit the drug and a companion diagnostic that can identify patients with FGFR alterations with the FDA in the second half of 2018.

FDA Approves Expanded Use of Agilent Assay as Keytruda CDx for Cervical Cancer

Physicians can now use the Dako PD-L1 IHC 22C3 pharmDx assay to identify cervical cancer patients who may benefit from the anti-PD1 immunotherapy.

MolecularMD, Genoptix Ink Marketing Agreement for CDx to Novartis CML Drug

The companion diagnostic test identifies patients taking the Novartis drug Tasigna who are candidates for treatment-free remission monitoring.

Jun 01, 2018

NeoGenomics, PPD Form Pathology, Molecular Testing Partnership

May 31, 2018

Qiagen, Freenome Partner to Improve Companion Diagnostic Development

May 31, 2018

Roche, Five Prime Therapeutics to Develop CDx Assays for Immuno-Oncology Drug Trials

May 24, 2018

Merck, Foundation Medicine to Develop Companion Diagnostics for Immunotherapy

May 22, 2018

Qiagen, HTG Molecular End First Project Under CDx Development Agreement

May 02, 2018

Foundation Medicine Doubles Q1 Revenues

May 01, 2018

Thermo Fisher Inks New Pharma Partnerships to Expand CDx Use of Oncomine NGS Test

Apr 17, 2018

At AACR, Immuno-Oncology Clinical Trials Offer Mixed Messages on Predictive Biomarkers

Premium

Apr 13, 2018

Illumina, Bristol-Myers Squibb Partner on Companion Dx Development for Immunotherapy

Apr 09, 2018

Commercial Payors Unlikely to Follow CMS Policy on NGS Cancer Panels in Short Term, Survey Suggests

Premium

Apr 03, 2018

PGDx to Develop Liquid Biopsy Companion Dx for Five Prime Therapeutics' Drug Candidate

Apr 02, 2018

Cancer Genetics Q4 Revenues Grow 4 Percent

Apr 02, 2018

Japanese Regulators Approve Myriad Genetics' BRACAnalysis Test

Feb 27, 2018

CMS-Proposed Coverage of NGS Cancer Tests Could Lead to Off-Label Scripts, Oncologists Worry

Premium

Feb 15, 2018

Foundation Medicine Coverage Initiated by Cowen

Feb 12, 2018

Proteomics International Investing in CPR Pharma Services

Feb 09, 2018

BMS Immunotherapy Combo Study Backs FoundationOne CDx Tumor Mutational Burden Indication

Premium

Jan 23, 2018

CMS Draft Coverage Policy on NGS Cancer Tests Raises Questions About Where Commercial Payors Stand

Premium

Jan 19, 2018

RNA Hybridization, Multiplex Assays Central to Bio-Techne's Growth Plans

Premium

Jan 16, 2018

Qiagen, HTG Molecular Begin Third Project Under CDx Development Pact

The Scan

Privacy Policy Information, Please

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

Moving the Parts About

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

This Week in Science

In Science this week: genetic overlap among many psychiatric disorders, and more.

Just Skip that Step

The Economist writes that an increasing number of scientific journals don't do peer review.

Jun

27

Featured Webinar

Clinical Utility of Liquid Biopsy for Targeted TKI Therapy in NSCLC

This webinar will present data from the FLAURA trial and show the clinical utility of liquid biopsy in identifying non-small-cell lung cancer (NSCLC) patients who may benefit from targeted TKI therapies.

Jul

19

Featured Webinar

Advances in NGS for Ultra-High Sensitivity Applications in Translational and Clinical Research

This webinar will discuss how ultra-highly sensitive and customizable targeted next-generation sequencing panels are applied in inherited disease research.

Main menu

Companion Diagnostics

What's Popular?

Sponsorships